These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9587856)

  • 41. [Presidential address: past, present and future of the cardiac valve substitutes].
    Wada J
    Nihon Kyobu Geka Gakkai Zasshi; 1982 Apr; 30(4):511-21. PubMed ID: 7119516
    [No Abstract]   [Full Text] [Related]  

  • 42. In response to: Grunkemeier GL, Starr A. Alternatives to randomization in surgical studies.
    Turina M
    J Heart Valve Dis; 1993 Jan; 2(1):123. PubMed ID: 8269106
    [No Abstract]   [Full Text] [Related]  

  • 43. In response to: Grunkemeier GL, Starr A. Alternatives to randomization in surgical studies.
    Huysmans H
    J Heart Valve Dis; 1993 Jan; 2(1):122-3. PubMed ID: 8269105
    [No Abstract]   [Full Text] [Related]  

  • 44. Safety and effectiveness considerations for clinical studies of visual prosthetic devices.
    Cohen ED
    J Neural Eng; 2007 Mar; 4(1):S124-9. PubMed ID: 17325410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early wear development in a novel mechanical heart valve prosthesis made from polymeric materials.
    Medart D; Steinseifer U; Reul H; Schmitz-Rode T
    J Heart Valve Dis; 2006 Sep; 15(5):710-5. PubMed ID: 17044379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Five-year follow up of the ATS mechanical heart valve.
    Emery RW; Krogh CC; Jones DJ; Nicoloff DM; Blake DP; Arom KV
    J Heart Valve Dis; 2004 Mar; 13(2):231-8. PubMed ID: 15086262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue engineered heart valves: will a clinical application be possible?
    Ozaki S
    Ann Thorac Cardiovasc Surg; 2005 Aug; 11(4):219-20. PubMed ID: 16148866
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunotoxicity testing guidance; availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 May; 64(87):24408-9. PubMed ID: 10558489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Twelve-year experience with the 19 mm Carpentier-Edwards pericardial aortic valve.
    Nakajima H; Aupart MR; Neville PH; Sirinelli AL; Meurisse YA; Marchand MA
    J Heart Valve Dis; 1998 Sep; 7(5):534-9. PubMed ID: 9793853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulatory, bioengineering and clinical requirements for cardiac valves: a new approach for a unique market.
    Lespinasse F; Grimaud E; Piwnica A
    J Heart Valve Dis; 1994 Sep; 3(5):461-7. PubMed ID: 8000576
    [No Abstract]   [Full Text] [Related]  

  • 55. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience.
    Goldsmith I; Lip GY; Mukundan S; Rosin MD
    J Heart Valve Dis; 1998 Sep; 7(5):574-9. PubMed ID: 9793859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial experience with the freestyle stentless aortic bioprosthesis.
    Wong SP; Legget ME; Raudkivi PJ
    N Z Med J; 2000 Jul; 113(1113):266-8. PubMed ID: 10935563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bayesian stopping guidelines for heart valve premarket approval studies.
    Grunkemeier GL; Wu Y; Wang L; Hamilton C
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):2813-7.e1. PubMed ID: 25135236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The FDA and regulatory issues in graft development.
    Abel D; Shulman M
    Semin Vasc Surg; 1999 Mar; 12(1):74-82. PubMed ID: 10100388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.